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Abstract (139/150) 
Background: X-linked adrenal hypoplasia congenita (AHC) is caused by mutations in 
DAX-1 (NR0B1) playing a key role in adrenal and reproductive development. 
Case Presentation: Herein we report a 2.5-year-old boy who presented with acute 
adrenal failure. Family history revealed unexplained death in 3 brothers of the patient’s 
mother during infancy. Molecular analysis of the DAX1 gene revealed the presence of a 
novel hemizygous mutation, c.870C>A in Exon 1, leading to the formation a premature 
stop codon. The same mutation was identified in the patient’s mother. The truncated 
mutant protein is most likely misfolded, sequestered in the endoplasmic reticulum and 
therefore cannot bind to and activate its target DNA sequences in the nucleus. 
Conclusions: DAX-1 mutation must be considered when diagnosis of primary 
adrenocortical insufficiency is made, especially if there is a history of unexplained death 
of maternal male relatives.  
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Introduction 
Hypoplasia/agenesis of adrenals leading to acute adrenal insufficiency with salt-
losing crisis as a fatal condition was first reported by Sikl in 1948 (1). In the 1990’s specific 
mutations of DAX-1 (Dosage-sensitive sex reversal – Adrenal hypoplasia congenital 
critical region on the X chromosome 1, known also as NR0B1 (OMIM 300473)), situated 
in Xp21, were described for the first time to cause X-linked adrenal hypoplasia congenita 
(AHC) (OMIM 300200). At that time, DAX-1 was recognized to play a key role not only in 
the development of the adrenal gland, but also in the development of the testis, ovary, 
pituitary gland and hypothalamus. These first reports linked X-linked AHC to glycerol 
kinase deficiency (GKD) and Duchenne muscular dystrophy (DMD), which helped to 
discover the localisation of the gene and its mutations causing X-linked AHC. Since then 
a wide phenotypic spectrum has been described, patients being mostly affected by 
frameshift or nonsense mutations that cause premature truncation of the protein.  
DAX-1encodes an orphan nuclear hormone receptor and interacts as a dominant 
negative regulator with other nuclear receptors, such as SF-1 to regulate gene expression 
(2). However, its exact biological role remains mainly unclear. In mice, deletion of exon 2 
in DAX-1 leads to impaired spermatogenesis but normal adrenal function (3). Interestingly, 
duplications of DAX-1 have been described in 46, XY disorder of sexual development 
(DSD). Possibly, this could mean that over-expression of DAX-1 suppresses male sexual 
development (4).  
Clinically, most males with X-linked AHC present with acute adrenal failure. Adrenal 
insufficiency with salt-losing crisis, which is lethal if untreated, can present either in the 
first 2 months of life or more gradually during childhood (5). Pubertal development is 
usually absent. However, some affected boys might develop pubertal sign up to Tanner 
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stage 3, when puberty stops due to disrupted hypothalamic and pituitary release of 
gonadotropin-releasing hormone and gonadotropins, respectively (6). Similarly, a few 
patients with DAX-1 mutation were reported to develop ACTH-dependent transient 
precocious pseudopuberty during infancy/childhood (7, 8).   
Herein, we present a novel DAX-1 mutation leading to X-linked AHC with acute 
adrenal failure in a 2.5-year-old boy. 
 
Case Presentation 
A 2.5-year-old boy who presented with vomiting and severe slackness was admitted 
to the emergency department. Physical examination revealed moderate dehydration, 
underweight (weight: 11 kg (Z-score -1.92), length: 92 cm (Z-score -0.57), normal 
developed male genitalia and hyperpigmented lips and nipples. Laboratory evaluation 
revealed hypoglycaemia (2.5 mmol/l), hyponatraemia (121 mmol/l), hypochloraemia (97 
mmol/l), hyperkalaemia (4.8 mmol/l), metabolic acidosis (pH 7.33, BE -11.9), low cortisol 
(1 nmol/l) and elevated ACTH (6040 pg/ml) concentration. Insulin was suppressed and 
growth hormone appropriately elevated ruling out other endocrine aetiologies for 
hypoglycaemia. A diagnosis of adrenal insufficiency was made and the boy was 
transferred to the intensive care unit for rehydration and substitution with hydrocortisone 
and sodium. After stabilization of vital parameters, the patient was switched to oral 
supplementation with hydrocortisone (14 mg/m2/day) and fludrocortisone (0.1 mg/day). 
The boy was discharged from hospital after a couple of days. Growth and psychomotor 
development have been normal since then. At 4 years of age, his weight is 17 kg (Z-score 
0.44) and height is 102.5 cm (Z-score 0.03).  
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The boy was born after normal pregnancy. Neonatal period was uneventful. He had 
a history of recurrent vomiting without diarrhea and increasing hyperpigmentation of the 
skin over the last 6 months before admission. Psychomotor development was reported to 
be normal. Family history revealed unexplained deaths in 3 brothers of the mother during 
infancy.  
On additional laboratory evaluation, congenital adrenal hyperplasia (low 17-
hydroxyprogesterone) and adrenoleukodystrophy (normal plasma concentration of very 
long-chain fatty acids) could be excluded. Negative anti-21-hydroxylase and anti-adrenal 
autoantibodies made an autoimmune Addison disease very unlikely. Given the family 
history DAX-1 mutation was assumed and a molecular analysis initiated.  
To this end, genomic DNA was extracted from peripheral blood leukocytes of the 
patient and the 2 exons of  DAX1 (RefSeq NG_009814.1) were amplified and sequenced 
(conditions available upon request). Direct sequencing of the PCR fragments revealed the 
presence of a novel hemizygous mutation, c.870C>A in Exon 1, leading to the substitution 
of a cystein at position 290 with a premature stop codon (p.Cys290Ter; Figure 1). The 
parents were also screened and his mother was shown to be carrier of the same mutation, 
as to be expected for a X-linked condition. 
To further analyze the molecular mechanism of the complete loss of function of the 
nonsense mutations, we explored the possibility of Nonsense-Mediated Decay (NMD) by 
stabilizing mRNA through the translation inhibitor cycloheximide. We demonstrated the 
loss-of-function of DAX1 is not due toNMD, as shown by the lack of differences in mRNA 
stability between WT and mutant DAX1under cycloheximide treatment (data not shown). 
Furthermore, Western Blot analysis showed no decrease in mutant protein quantity or 
stability, although the detected protein was, as expected, shorter (data not shown).  
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Molecular models of the wild type and mutant protein were created with the online 
tool I-TASSER, based on homology modelling. Furthermore, the model was refined with 
a 5ns refinement molecular dynamics run using YASARA (yasara.org) and finally depicted 
using PyMol (pymol.org). Thep.Cys290 stop mutation lead to a C-terminal truncation of 
180 amino acids from DAX1 (Figure 2). The homology modelling predicts that the folding 
of the mutant DAX1 is disrupted and, hence, significantly different compared to the 
predicted protein folding of the WT DAX1. Accordingly, immunofluorescence experiments 
performed in transfected COS-1 cells showed that whereas WT DAX1 correctly 
concentrated in the nuclei, the mutant protein was detectable only in the cytoplasm of 
transfected COS1 cells, and is therefore prevented to exert its function as a transcription 
factor thus leading to loss-of-function and disease (data not shown).   
 
Discussion 
X-linked adrenal hypoplasia congenita is caused by mutations in DAX1 gene. To 
date even though over one hundred individuals and relatives with X-linked AHC have been 
reported in the literature, the exact prevalence of NR0B1 mutations causing adrenal 
insufficiency is not clear. Studies suggest an occurrence of X-linked AHC of around 
1:140,000 to 1:1,200,000 children (or between 1:70,000 and 1:600,000 males) (5). 
Lin et al reported finding DAX1 mutations in all patients with adrenal insufficiency of 
their cohort (8 cases of a cohort of 117 patients) when family history revealed adrenal 
failure or unexpected death in males together with a history of arrested or absent puberty. 
This underlines the importance of taking an exact family history suggesting any insight 
into possible adrenal disease (5). In line with such findings and the fact that DAX-1 
mutations follow an X-linked pattern of inheritance, family history of three maternal male 
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relatives dying during neonatal period was suggestive for DAX-1 defect being 
retrospectively the putative cause of their early death. 
Genetic analysis revealed a novel hemizygous mutation, c.870C>A, in Exon 1. This 
mutation led to the formation of a premature stop codon resulting in a C-terminal truncation 
of 180 amino acids from DAX1. The DAX1 gene encodes a protein that belongs to the 
nuclear hormone receptor superfamily with an amino-terminal region and a carboxyl-
terminal region (2). Nonsense and frameshift mutations can be located throughout the 
NR0B1 gene. Missense mutations tend to be more prevalent in certain regions of the 
ligand-like binding domain, in highly conserved amino acids (9). The C terminus shows 
characteristics of a nuclear hormone receptor ligand-binding domain. In 1997, Lalli et al. 
discovered that the DAX1 C terminus contains transcriptional silencing activity, which can 
be transferred to a heterologous DNA-binding domain (10). Nakae found that especially 
mutations in the C-terminus of the DAX-1 protein cause AHC. They postulated that the C-
terminal domain of the DAX-1 protein is important for normal adrenal gland development. 
Even impairment of 11 amino acids in this region can lead to disrupted adrenal cortical 
differentiation (11).  
Phenotypes in patients harbouring a DAX 1 mutation show wide heterogeneity. As 
there is no genotype-phenotype correlation, DAX-1 mutation does not predict which 
clinical characteristics can be expected. Moreover, age of onset of AHC and the position 
of the mutation do not correlate (11). Within the same family harbouring the same mutation 
onset of clinical manifestation can vary. This may also be suggested in our family where 
manifestation of adrenal insufficiency in our patient occurred only in the third year 
compared to his uncles with suggested DAX1 mutation who died in the first year. Such 
findings suggest various degrees of penetrance due to co-modulating and/or epigenetic 
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or nongenetic factors influencing DAX-1 activity and integrity and thereby the clinical 
course of AHC (12). 
In conclusion, we identified a novel hemizygous mutation in a patient with X-linked 
AHC. This mutation led to the formation of a premature stop codon, resulting in a C-
terminal truncation of 180 amino acids from DAX1, which is probably misfolded, 
sequestered in the endoplasmic reticulum and most likely degraded. Differentiating 
adrenal insufficiency due to DAX-1 mutation from other causes is of great importance 
since it has implications for future follow-up and treatment as well as family planning and 
counselling. 
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Figure Legend 
 
Fig. 1 Mutation analysis 
Electropherograms of directly sequenced PCR-amplified fragments from genomic DNA of 
the patients, his parents (mother and father) and a control showing a C to A exchange in 
Exon 1 (position c.870), leading to the substitution of a cystein at position 290 with a 
premature stop codon (p.Cys290Ter). The mutation is hemizygous in the patient and 
heterozygous in the mother, as to be expected for a X-linked mode of inheritance. 
 
Fig. 2 Model of wild type and p.Cys290Stop DAX1 mutant proteins 
A. DAX1 consist of two domains, the N-terminal DNA-binding domain and the C-terminal 
putative Ligand-binding Domain. Predicted wild-type DAX1 protein model.  
B. The DAX1 p.Cys290 stop mutation leads to a loss of 180 amino acids, which in turn 
results in a predicted change in protein folding according to homology modelling.  
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